<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have recently reported the neuroprotective effect of pranlukast (ONO-1078), a <z:chebi fb="0" ids="23511,32460">cysteinyl</z:chebi> <z:chebi fb="0" ids="25029">leukotriene</z:chebi> receptor-1 (CysLT1) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats and mice </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we further determined whether the effect of pranlukast is long lasting and related to the formation of a glial scar in cerebral ischemic mice </plain></SENT>
<SENT sid="2" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>After <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, pranlukast (0.1 mg/kg) was injected intraperitoneally for 5 consecutive days </plain></SENT>
<SENT sid="4" pm="."><plain>Neurological deficits and sensorimotor function were determined during 70 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Brain lesion and glial scar formation were detected at the end of the experiment </plain></SENT>
<SENT sid="6" pm="."><plain>Pranlukast did not reduce mortality, but significantly improved neurological deficits and promoted sensorimotor recovery during 70 days </plain></SENT>
<SENT sid="7" pm="."><plain>At the end of the experiment, pranlukast significantly reduced lesion volume, and increased neuron densities in the cortex and hippocampal CA1 region in the ischemic hemispheres </plain></SENT>
<SENT sid="8" pm="."><plain>Importantly, pranlukast also remarkably reduced the thickness of a scar wall in the ischemic hemispheres </plain></SENT>
<SENT sid="9" pm="."><plain>These findings indicate that pranlukast has a long-lasting protective effect on focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice, and inhibit the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced glial scar formation, providing further evidence of the therapeutic potential of pranlukast in the treatment of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>